| Size | Price | Stock | Qty |
|---|---|---|---|
| 100mg |
|
||
| 250mg |
|
||
| 500mg |
|
||
| Other Sizes |
| Targets |
Dymanthine targets intestinal helminths (parasitic worms). Its mechanism of action as an anthelmintic is not fully detailed in standard databases, but it is an agent used for the research of multiple intestinal helminthic infestations. It likely disrupts the metabolism or neuromuscular function of the parasites, leading to their expulsion or death. As a veterinary anthelmintic, it is effective against a variety of intestinal worms.
|
|---|---|
| ln Vitro |
In vitro, dymanthine has been evaluated for its anthelmintic activity against various intestinal parasites. As a veterinary anthelmintic, its efficacy has been demonstrated in basic studies. Detailed in vitro activity data is limited in publicly available sources.
|
| ln Vivo |
In vivo, dymanthine has been used as an anthelmintic in veterinary medicine. It has been studied for its potential in treating multiple intestinal helminthic infestations. It is effective against a variety of intestinal worms. Clinical studies have been conducted in human patients.
|
| Enzyme Assay |
In vitro anthelmintic assays for dymanthine would involve incubating the compound with various species of parasitic worms in culture media. The viability and motility of the worms would be assessed over time. IC50 or EC50 values would be calculated from dose-response curves. However, detailed protocols are not widely documented in standard databases.
|
| Cell Assay |
In vitro cellular assays for dymanthine are not typical, as it is an anthelmintic targeting whole organisms rather than cultured cells. However, its effects on parasite metabolism or neuromuscular function could be studied in cell-based models if applicable.
|
| Animal Protocol |
In vivo animal studies for dymanthine would involve administering the compound to animals infected with intestinal helminths. The reduction in worm burden would be assessed by fecal egg count reduction or by counting worms at necropsy. Efficacy would be compared to vehicle and reference anthelmintics.
|
| ADME/Pharmacokinetics |
Dymanthine has a molecular weight of 297.56 g/mol and a molecular formula of C20H43N. It is a solid. It is typically stored as a powder at -20°C for up to 3 years or in solvent at -80°C for up to 6 months. It is soluble in DMSO (1 mg/mL). It is a veterinary anthelmintic.
|
| Toxicity/Toxicokinetics |
Dymanthine is an anthelmintic agent. As a veterinary drug, its toxicity profile has been evaluated in animals. It may cause irritation to the skin, eyes, and respiratory tract. Inhalation may cause chemical pneumonitis and pulmonary edema. It is corrosive.
|
| Additional Infomation |
N,N-Dimethyl-1-octadecaneamine is a clear, yellow liquid with a fishy odor. It is insoluble in water and has a lower density than water, therefore it floats on water. Contact may irritate the skin, eyes, and mucous membranes. Poisoning may occur through ingestion, inhalation, or skin absorption. It is used in the manufacture of other chemicals. Diamantadine is a tertiary amine compound.
Dymanthine (N,N-Dimethyloctadecan-1-amine) is an anthelmintic agent. It has been used in veterinary medicine. It has been studied for multiple intestinal helminthic infestations. It is available for research purposes only. |
| Molecular Formula |
C20H43N
|
|---|---|
| Molecular Weight |
297.57
|
| Exact Mass |
297.339
|
| CAS # |
124-28-7
|
| Related CAS # |
1613-17-8 (hydrochloride)
|
| PubChem CID |
15365
|
| Appearance |
White to yellow <23°C solid powder,>23°C liquid
|
| Density |
0.8±0.1 g/cm3
|
| Boiling Point |
348.5±5.0 °C at 760 mmHg
|
| Melting Point |
23 °C
|
| Flash Point |
153.8±5.2 °C
|
| Vapour Pressure |
0.0±0.8 mmHg at 25°C
|
| Index of Refraction |
1.450
|
| LogP |
9.1
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
1
|
| Rotatable Bond Count |
17
|
| Heavy Atom Count |
21
|
| Complexity |
177
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CCCCCCCCCCCCCCCCCCN(C)C
|
| InChi Key |
NAPSCFZYZVSQHF-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C20H43N/c1-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20-21(2)3/h4-20H2,1-3H3
|
| Chemical Name |
N,N-dimethyloctadecan-1-amine
|
| Synonyms |
Adogen 342D; ADMA 18; Dymanthine
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
|---|
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.3606 mL | 16.8028 mL | 33.6055 mL | |
| 5 mM | 0.6721 mL | 3.3606 mL | 6.7211 mL | |
| 10 mM | 0.3361 mL | 1.6803 mL | 3.3606 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
